BibTex format
@article{Layhadi:2026:10.1111/all.70280,
author = {Layhadi, JA and Gutierrez, LC and Keane, ST and Fulton, W and Samson, NA and Wu, LYD and Filipaviciute, P and Hikmawati, P and Fedina, O and JimenezGil, A and Durham, SR and Scadding, G and Tropper, G and Vézina, L and Colin, P and Ree, RV and Shamji, MH},
doi = {10.1111/all.70280},
journal = {Allergy},
pages = {2156--2171},
title = {Fel d 1expressing plantderived bioparticle: a novel treatment for cat allergy},
url = {http://dx.doi.org/10.1111/all.70280},
volume = {81},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BackgroundAllergen immunotherapy (AIT) is the only disease-modifying therapeutic approach for cat allergy, though it requires at least three years of treatment and can potentially induce severe systemic reactions. Plant-derived bioparticles expressing Fel d 1 allergen (Fel d 1 eBP) have been developed as a novel therapeutic candidate for cat allergy. We aimed to investigate the allergenicity and immunogenicity profile of Fel d 1 eBP.MethodsFel d 1 eBP was synthesised in vivo in Nicotiana benthamiana and confirmed by cryo-electron microscopy and tomography. Immune modulatory properties of purified natural Fel d 1 (nFel d 1) and Fel d 1 eBP were assessed at T and B cells by flow cytometry in 12 cat-allergic subjects (CA) and 12 non-atopic controls (NAC). Single-cell RNA-seq was used to assess molecular mechanisms of Fel d 1 eBP immune skewing. The safety of Fel d 1 eBP was assessed by measuring basophil responsiveness in whole blood and further confirmed in vivo by its administration as a skin prick test (SPT) in 20 cat-allergic individuals.ResultsFel d 1 eBP was shown to be a strong inducer of Th1 cells (p < 0.05) and IL-10+ non-Th2 cells (p < 0.05) in CA subjects. Fel d 1 eBP showed a stronger trend for inducing IL-10+ Breg cells compared to nFel d 1, peaking at 3 μg/mL. scRNA-seq analyses demonstrated that Fel d 1 eBP targets the induction of protective metallothionein genes, CCL18+ monocytes and naïve B cells that are interferon responsive and metabolically activated. Moreover, Fel d 1 eBP demonstrated reduced capacity to elicit basophil activation (p < 0.001) and histamine release (p < 0.01), indicating their hypoallergenic nature. Administration of titrated doses of Fel d 1 eBP through skin prick test revealed that they are well-tolerated with reduced mean wheal compared to native Fel d 1 in an open-label Phase 0 study (all, p < 0.001).ConclusionsWe demonstrate th
AU - Layhadi,JA
AU - Gutierrez,LC
AU - Keane,ST
AU - Fulton,W
AU - Samson,NA
AU - Wu,LYD
AU - Filipaviciute,P
AU - Hikmawati,P
AU - Fedina,O
AU - JimenezGil,A
AU - Durham,SR
AU - Scadding,G
AU - Tropper,G
AU - Vézina,L
AU - Colin,P
AU - Ree,RV
AU - Shamji,MH
DO - 10.1111/all.70280
EP - 2171
PY - 2026///
SN - 0105-4538
SP - 2156
TI - Fel d 1expressing plantderived bioparticle: a novel treatment for cat allergy
T2 - Allergy
UR - http://dx.doi.org/10.1111/all.70280
UR - https://doi.org/10.1111/all.70280
VL - 81
ER -